Purification and characterization of a human membrane protein that activates the alternative complement pathway and allows the deposition of homologous complement C3.
Open Access
- 1 January 1995
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 181 (1) , 115-125
- https://doi.org/10.1084/jem.181.1.115
Abstract
A human myeloid cell subline, P39+, is found to be a target for human complement (C) via the alternative pathway and to allow the deposition of multiple C3 fragments on its membranes, though expressing the complement regulatory proteins decay-accelerating factor and membrane cofactor protein. The parent cell line, P39-, which is phenotypically similar to the P39+ subline, does not allow the deposition of homologous C3 fragments. In this study, we established a monoclonal antibody, M161 Ab, which reacted with P39+ but not P39- cells. This Ab recognized a 43-kD protein in P39+ cell lysate transblotted onto nitrocellulose. Using this Ab as a probe, we purified the 43-kD protein, namely, M161 antigen (Ag). M161 Ag had a basic isoelectric point (pI), 9.3-9.4 by chromatofocusing, and was precipitated as an insoluble material at the pI point. The purified M161 Ag was a single-chain protein and did not possess N- or O-linked carbohydrates. When the purified M161 Ag was transblotted onto nitrocellulose and incubated with Mg(2+)-EGTA serum, human C3 fragments were efficiently deposited on M161 Ag. The major species of the deposited C3 fragments was C3b. Furthermore, the C3 fragments bound to the M161 Ag were detached by 1 M hydroxylamine, suggesting that a covalent ester linkage sustains M161 Ag-C3b interaction. NH2-terminal amino acid analysis revealed that M161Ag is a novel membrane protein. Hence, it appeared that M161 Ag is a potent activator of human alternative complement pathway on human cells that activates homologous C3 and allows the deposition of C3b on itself. Thus, under some conditions, homeostasis of complement is maintained even on human cells, not only by the complement regulatory proteins, but also by membrane C3-activating molecules on which C3b is deposited.Keywords
This publication has 47 references indexed in Scilit:
- Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis.The Journal of Immunology, 1993
- Interferon amplifies complement activation by Burkitt's lymphoma cellsNature, 1985
- Natural release of covalently bound C3b from cell surfaces and the study of this phenomenon in the fluid-phase system.The Journal of Immunology, 1984
- Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes.Proceedings of the National Academy of Sciences, 1984
- Alternative pathway of complement activation by human lymphoblastoid B and T cell lines.The Journal of Immunology, 1983
- Identification of the C3bi receptor of human monocytes and macrophages by using monoclonal antibodies.Proceedings of the National Academy of Sciences, 1983
- Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.The Journal of Immunology, 1982
- A new complement-dependent bactericidal factor found in nonimmune mouse sera: specific binding to polysaccharide of Ra chemotype Salmonella.The Journal of Immunology, 1982
- A fluorometric method for determination of C3b inactivatorClinica Chimica Acta; International Journal of Clinical Chemistry, 1982
- Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Proceedings of the National Academy of Sciences, 1979